Alkermes Plc (ALKS)

Jan 2, 2025, 4:00 PM EST - 15 days ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 4:00 PM EST - 7 weeks ago

Alkermes to Participate in Upcoming Investor Conferences

Nov 24, 2024, 9:58 AM EST - 7 weeks ago

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 11, 2024, 4:00 PM EST - 2 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 7, 2024, 7:00 AM EST - 2 months ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Oct 24, 2024, 1:04 PM EDT - 3 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 7:00 AM EDT - 3 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 17, 2024, 4:00 PM EDT - 3 months ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Sep 25, 2024, 8:00 AM EDT - 4 months ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Sep 23, 2024, 7:00 AM EDT - 4 months ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Sep 13, 2024, 7:00 AM EDT - 4 months ago

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Aug 28, 2024, 4:00 PM EDT - 5 months ago

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 7:00 AM EDT - 5 months ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Jul 24, 2024, 2:20 PM EDT - 6 months ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 7:00 AM EDT - 6 months ago

Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 4:00 PM EDT - 6 months ago

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Jun 3, 2024, 7:00 AM EDT - 8 months ago

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

May 28, 2024, 7:00 AM EDT - 8 months ago

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

May 17, 2024, 8:27 AM EDT - 8 months ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 14, 2024, 7:00 AM EDT - 8 months ago

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

May 2, 2024, 7:00 AM EDT - 9 months ago

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

May 1, 2024, 7:00 AM EDT - 9 months ago

Alkermes plc Reports First Quarter 2024 Financial Results

Apr 24, 2024, 7:00 AM EDT - 9 months ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Apr 17, 2024, 4:00 PM EDT - 9 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2024

Apr 9, 2024, 4:29 PM EDT - 10 months ago

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 9, 2024, 9:49 AM EDT - 10 months ago

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Apr 9, 2024, 7:00 AM EDT - 10 months ago

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Apr 8, 2024, 7:00 AM EDT - 10 months ago

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Mar 7, 2024, 7:00 AM EST - 11 months ago

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Feb 15, 2024, 3:08 PM EST - 1 year ago

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:00 AM EST - 1 year ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Feb 8, 2024, 4:00 PM EST - 1 year ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Jan 26, 2024, 3:33 PM EST - 1 year ago

Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage

Jan 3, 2024, 4:00 PM EST - 1 year ago

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

Dec 14, 2023, 6:05 AM EST - 1 year ago

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

Nov 15, 2023, 7:00 AM EST - 1 year ago

Alkermes Completes Separation of Oncology Business

Nov 10, 2023, 2:46 PM EST - 1 year ago

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate

Nov 7, 2023, 4:00 PM EST - 1 year ago

Alkermes to Participate in the Jefferies London Healthcare Conference

Oct 31, 2023, 5:08 PM EDT - 1 year ago

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

Oct 25, 2023, 4:28 PM EDT - 1 year ago

Alkermes plc (ALKS) Q3 2023 Earnings Call Transcript

Oct 25, 2023, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Oct 18, 2023, 4:00 PM EDT - 1 year ago

Alkermes to Report Third Quarter Financial Results on October 25, 2023

Oct 10, 2023, 5:00 PM EDT - 1 year ago

Mural Oncology to Host Investor Webcast on October 17

Oct 10, 2023, 7:00 AM EDT - 1 year ago

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

Sep 7, 2023, 7:00 AM EDT - 1 year ago

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

Aug 31, 2023, 7:00 AM EDT - 1 year ago

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

Aug 30, 2023, 11:27 AM EDT - 1 year ago

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

TEVA